Well friends, it’s come to my attention that one little pharmaceutical company just gave a major middle finger to Eli Lilly and Novo Nordisk. The company? Viking Therapeutics (VKTX) who in fact, just dropped some data that has overpaid (and overweight) Wall Street analysts licking their chops. 

(Source: Giphy) 

In short, Viking’s experimental obesity pill, VK2735, is showing some seriously promising results. Patients on the highest dose—a solid 100 mg—lost a whopping 8.2% of their body weight in just 28 days. That’s 6.8% more than those poor souls stuck on placebo pills. In fact, you could almost hear the collective “I’ll have what she’s having” from the biotech crowd when these results dropped. 

(Source: Barrons) 

Now, if you’re thinking, “Wait, haven’t I heard this story before?” you’re not wrong. Eli Lilly and Novo Nordisk have already cornered the market with their injectable GLP-1 drugs (Wegovy, Mounjaro, Zepbound—take your pick). But here’s the thicc and juicy part: Viking’s pill is oral. That’s right - no more needles you sissy’s. All we have to do now is just pop a daily pill and watch the pound melt away. Meaning, Viking has just created the Uber Eats of weight loss drugs: fast, convenient, and terrible news for your liver. 

(Source: Giphy) 

What’s more, is that this isn’t just a one hit wonder either. Back in March, Viking reported that a 40 mg dose of VK2735 led to a 5.3% weight loss after 28 days. Not bad at all, but this latest 100 mg dose? It’s like comparing Joe Flacco to Joe Montana. And the best part? No one bailed on the highest dose. Sure, there was some mild nausea reported, but simply put, no one died (a.k.a. Bigly win). 

(Source: Seeking Alpha) 

Naturally, Viking’s stock went soaring this morning - 25% in pre-market trading, to be exact. But like DJT last Friday, gravity ultimately won, pulling Vikings stock back down to a mere 1.2% gain. Now, of course, while that may seem like a Monday morning ball-buster, keep in mind that Viking is still cruising 291% YTD. And after these jaw-dropping trial results, Wall Street clearly thinks this little biotech might just be the next big thing in the $150 billion weight-loss market.

For instance, JPMorgan seems pretty convinced, giving them an “Overweight” rating—Wall Street’s equivalent of a gold star. They’re betting on VK2735 to become a viable player (or partner) in the obesity market. And why not? The drug’s showing the best weight loss numbers we’ve seen from an oral treatment, and it’s still only in early-stage trials.

(Source: TipRanks) 

Plus, Viking’s developing an injectable version of VK2735, just in case people want to keep their options open. Because, you know, nothing says “we’re covering all bases” like giving consumers the choice between swallowing a pill or stabbing themselves in the leg.

In the end, Viking Therapeutics is crushing its start for the week. And if their higher doses of VK2735 continue to deliver, they might just end up clapping their competitors for total dominance - especially given their stock has already quadrupled this year. 

Now ff course, do what you will with this information, but even though I firmly believe that the ones who create the problems also create the solutions (*cough* Big Pharma *cough*), there’s still money to be made. And that money just may be supercharged with Viking Therapeutics going forward. 

In the meantime, don’t be dumb and please place your bets accordingly - and as always, stay safe and stay frosty, friends! Until next time…

P.S. Our “Wild Friday” alert delivered a 116% move in just minutes… If you’re tired about hearing about these trades AFTER the fact (and how we’re averaging a 100%+ winner every single week) Click here for the details on how to become a Stocks.News Premium Member.

Stocks.News holds positions in Uber as mentioned in the article.